Abstract
This chapter focuses on the rationale, challenges and methodological considerations for evaluating the economics of N-of-1 trials. First, we outline the rationale for undertaking an economic evaluation alongside an N-of-1 trial, by describing two key economic questions that are likely to be of interest to researchers, policy makers and clinicians. Then we outline the methods for undertaking an economic evaluation, highlighting some methodological aspects that are of particular relevance for the economics of N-of-1 trials as opposed to more traditional clinical trials. Finally, we acknowledge that the economic evaluation of N-of-1 trials is still in its infancy. We reflect on the research agenda to further develop the potential for N-of-1 trials to inform optimal decision-making around treatment and the appropriate allocation of health care resources.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Briggs A (1999) Economics notes: handling uncertainty in economic evaluation. BMJ 319:120
Cairns J (1994) Valuing future benefits. Health Econ 3:221–229
Claxton K (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18:341–364
Drummond MF, Sculpher MJ, Torrance GW, O’brien B, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, New York
Gabler NB, Duan N, Vohra S, Kravitz RL (2011) N-of-1 trials in the medical literature: a systematic review. Med Care 49:761–768
Glick H, Doshi J, Sonnad S, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, Oxford
Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
Harris AH, Hill SR, Chin G, LI JJ, Walkom E (2008) The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Making 28:713–722
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, Force IHE, Force, I. H. E. E. P. G.-C. G. R. P. T. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231–250
Karnon J, Qizilbash N (2001) Economic evaluation alongside n-of-1 trials: getting closer to the margin. Health Econ 10:79–82
Kravitz RL, Duan N, White RH (2008) N-of-1 trials of expensive biological therapies: a third way? Arch Intern Med 168:1030–1033
Kravitz RL, Paterniti DA, Hay MC, Subramanian S, Dean DE, Weisner T, Vohra S, Duan N (2009) Marketing therapeutic precision: potential facilitators and barriers to adoption of n-of-1 trials. Contemp Clin Trials 30:436–445
Lancsar E, Louviere J (2008) Estimating individual level discrete choice models and welfare measures using best worst choice experiments and sequential best worst MNL. Centre for the Study of Choice, University of Technology, Sydney
Mcmillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, Wheeler AJ (2013) Patient-centered approaches to health care: a systematic review of randomized controlled trials. Med Care Res Rev 70:567–596
Nice (2004) Guide to the methods of technology appraisal. National Institute for Clinical Excellence (NICE), London
Pharmaceutical Benefits Advisory Committee (2013) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.4). Australian Government Department of Health, Canberra
Pope JE, Prashker M, Anderson J (2004) The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J Rheumatol 31:140–149
Preference Collaborative Review Group (2008) Patients’ preferences within randomised trials: systematic review and patient level meta-analysis. BMJ 337:a1864. doi:10.1136/bmj.a1864
Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S (2005) Best practices for economic evaluation alongside clinical trials: an ISPOR RCT-CEA task force report. Value Health 8:521–533
Rawls J (1999) A theory of justice. Belknap Press of Harvard University Press, Cambridge, MA
Robinson A, Parkin D (2002) Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni. Health Econ 11:649–651
Ruta DA, Garratt AM, Leng M, Russell IT, Macdonald LM (1994) A new approach to the measurement of quality of life. The patient-generated index. Med Care 32:1109–1126
Schulman K, Seils D (2003) Clinical economics. In: Max M, Lynn J (eds) Interactive textbook on clinical symptom research. National Institutes of Health, Bethesda
Scuffham PA, Whitty JA, Mitchell A, Viney R (2008a) The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4. Pharmacoeconomics 26:297–310
Scuffham PA, Yelland MJ, Nikles J, Pietrzak E, Wilkinson D (2008b) Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience. Value Health 11:97–109
Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ, Pillans PI, Bashford G, Del Mar C, Schluter PJ, Glasziou P (2010) Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med 25:906–913
Smith DH, Gravelle H (2001) The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care 17:236–243
Thompson S, Barber J (2000) How should cost data in pragmatic randomised controlled trials be analysed? BMJ 320:1197–20
Torgerson D (1999) Discounting. BMJ 319:914–915
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Whitty, J.A., Byrnes, J.M., Scuffham, P.A. (2015). The Economics of N-of-1 Trials. In: Nikles, J., Mitchell, G. (eds) The Essential Guide to N-of-1 Trials in Health. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7200-6_13
Download citation
DOI: https://doi.org/10.1007/978-94-017-7200-6_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7199-3
Online ISBN: 978-94-017-7200-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)